-

Robbins LLP is Investigating Allegations that the Officers and Directors of Portillo’s Inc. (PTLO) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Portillo’s Inc. (NASDAQ: PTLO) to determine whether certain Portillo’s Inc. officers and directors violated securities laws and breached fiduciary duties to shareholders. Portillo's Inc. owns and operates fast casual restaurants in the United States.

Robbins LLP is Investigating Allegations that the Officers and Directors of Portillo’s Inc. (PTLO) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

Share

On August 5, 2025, Portillo’s reported second quarter 2025 financial results. Although the Company maintained its target of 12 new restaurants and same-restaurant sales growth of 1% to 3%, Portillo’s reduced its fiscal 2025 revenue growth target and lowered its adjusted EBITDA growth expectations. Portillo’s also disclosed that same-restaurant sales increased only 0.7% during the quarter, while transactions declined 1.4%.

Then, on September 10, 2025, Portillo’s announced a business update and strategic reset. Among other things, Portillo’s disclosed that it expected third quarter same-restaurant sales to decline between 2.0% and 2.5%. The Company also cut its fiscal 2025 unit-growth target from 12 new restaurants to 8 new restaurants, lowered its same-restaurant sales outlook from growth of 1% to 3% to a decline of 1% to 1.5%, reduced its restaurant-level adjusted EBITDA margin target, and lowered its adjusted EBITDA outlook. Following these disclosures, Portillo’s stock price declined sharply.

What Now: If you lost money in your investment of Portillo’s Inc., contact Robbins LLP for more information about your rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas, Jr.
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against Portillo’s Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:PTLO

Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Nano-X Imaging Ltd. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nano-X Imaging Ltd. (NASDAQ: NNOX) securities between March 31, 2025 and April 17, 2026. Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Al...

Investor Notice: Robbins LLP Informs Investors of the ADMA Biologics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026. ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.For more information, submit...

Investor Notice: Robbins LLP Informs Investors of the Erasca, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025 and April 26, 2026. Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...
Back to Newsroom